185 related articles for article (PubMed ID: 9000127)
21. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
Liang SX; Richardson DR
Carcinogenesis; 2003 Oct; 24(10):1601-14. PubMed ID: 12869419
[TBL] [Abstract][Full Text] [Related]
22. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Sowa Y; Orita T; Minamikawa S; Nakano K; Mizuno T; Nomura H; Sakai T
Biochem Biophys Res Commun; 1997 Dec; 241(1):142-50. PubMed ID: 9405248
[TBL] [Abstract][Full Text] [Related]
24. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
25. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.
Unger T; Sionov RV; Moallem E; Yee CL; Howley PM; Oren M; Haupt Y
Oncogene; 1999 May; 18(21):3205-12. PubMed ID: 10359526
[TBL] [Abstract][Full Text] [Related]
26. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.
Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA
Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040
[TBL] [Abstract][Full Text] [Related]
27. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.
Zeng PY; Berger SL
Cancer Res; 2006 Nov; 66(22):10701-8. PubMed ID: 17108107
[TBL] [Abstract][Full Text] [Related]
28. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
[TBL] [Abstract][Full Text] [Related]
29. p53-mediated transcription induces resistance of DNA to UV inactivation.
Huang J; Logsdon N; Schmieg FI; Simmons DT
Oncogene; 1998 Jul; 17(4):401-11. PubMed ID: 9696032
[TBL] [Abstract][Full Text] [Related]
30. Epstein-barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally.
Lin CS; Kuo HH; Chen JY; Yang CS; Wang WB
J Mol Biol; 2000 Oct; 303(1):7-23. PubMed ID: 11021966
[TBL] [Abstract][Full Text] [Related]
31. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress.
Zhan Q; Kontny U; Iglesias M; Alamo I; Yu K; Hollander MC; Woodworth CD; Fornace AJ
Oncogene; 1999 Jan; 18(2):297-304. PubMed ID: 9927186
[TBL] [Abstract][Full Text] [Related]
33. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth.
Pellegata NS; Cajot JF; Stanbridge EJ
Oncogene; 1995 Jul; 11(2):337-49. PubMed ID: 7624148
[TBL] [Abstract][Full Text] [Related]
34. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions.
Subler MA; Martin DW; Deb S
Oncogene; 1994 May; 9(5):1351-9. PubMed ID: 8152795
[TBL] [Abstract][Full Text] [Related]
35. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation.
Mayr GA; Reed M; Wang P; Wang Y; Schweds JF; Tegtmeyer P
Cancer Res; 1995 Jun; 55(11):2410-7. PubMed ID: 7757994
[TBL] [Abstract][Full Text] [Related]
36. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity.
Kawamura M; Yamashita T; Segawa K; Kaneuchi M; Shindoh M; Fujinaga K
Oncogene; 1996 Jun; 12(11):2361-7. PubMed ID: 8649776
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
Kong XT; Gao H; Stanbridge EJ
J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
[TBL] [Abstract][Full Text] [Related]
38. Cell-specific modulation of the papovavirus promoters by tumor-suppressor protein p53 in the absence of large T-antigen.
Das GC; Shivakumar CV; Todd SD
Oncogene; 1995 Feb; 10(3):449-55. PubMed ID: 7845669
[TBL] [Abstract][Full Text] [Related]
39. Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function.
Zhang W; McClain C; Gau JP; Guo XY; Deisseroth AB
Cancer Res; 1994 Aug; 54(16):4448-53. PubMed ID: 8044794
[TBL] [Abstract][Full Text] [Related]
40. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
